MX2024000517A - Tratamiento de enfermedades inflamatorias. - Google Patents

Tratamiento de enfermedades inflamatorias.

Info

Publication number
MX2024000517A
MX2024000517A MX2024000517A MX2024000517A MX2024000517A MX 2024000517 A MX2024000517 A MX 2024000517A MX 2024000517 A MX2024000517 A MX 2024000517A MX 2024000517 A MX2024000517 A MX 2024000517A MX 2024000517 A MX2024000517 A MX 2024000517A
Authority
MX
Mexico
Prior art keywords
treatment
inflammatory diseases
interferonopathies
compound
ifna
Prior art date
Application number
MX2024000517A
Other languages
English (en)
Spanish (es)
Inventor
René Alexandre Galien
Justine Dao
Magdalena Yonkova Petkova
Christian Alexander Seemayer
Edouard Hellot
Rincon Natalia Rueda
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2024000517A publication Critical patent/MX2024000517A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2024000517A 2021-07-12 2022-07-11 Tratamiento de enfermedades inflamatorias. MX2024000517A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305971 2021-07-12
EP22315039 2022-02-24
PCT/EP2022/069362 WO2023285405A1 (en) 2021-07-12 2022-07-11 Treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
MX2024000517A true MX2024000517A (es) 2024-01-31

Family

ID=82748704

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000517A MX2024000517A (es) 2021-07-12 2022-07-11 Tratamiento de enfermedades inflamatorias.

Country Status (9)

Country Link
US (1) US20240325404A1 (enExample)
EP (1) EP4370128A1 (enExample)
JP (1) JP2024524631A (enExample)
KR (1) KR20240035480A (enExample)
AU (1) AU2022310901A1 (enExample)
CA (1) CA3225221A1 (enExample)
IL (1) IL309946A (enExample)
MX (1) MX2024000517A (enExample)
WO (1) WO2023285405A1 (enExample)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717260D0 (en) * 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
AU2022310901A1 (en) 2024-02-22
JP2024524631A (ja) 2024-07-05
EP4370128A1 (en) 2024-05-22
US20240325404A1 (en) 2024-10-03
KR20240035480A (ko) 2024-03-15
IL309946A (en) 2024-03-01
WO2023285405A1 (en) 2023-01-19
CA3225221A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
MX2022015812A (es) Inhibidores de cisteina proteasas y sus metodos de uso.
JOP20230326A1 (ar) أجزاء علاجية جديدة واستخداماتها
ZA202403923B (en) Heterocyclic compounds as immunomodulators
MY209609A (en) Immunomodulators, compositions and methods thereof
MX2021004431A (es) Procesos novedosos.
ATE466085T1 (de) Protease-resistente modifizierte interferon alpha polypeptide
EA200100872A1 (ru) Композиция валдекоксиба
MX2022009390A (es) Compuestos de unión a il-7r¿¿c.
MY205028A (en) Protein for treatment of inflammatory diseases
MX2024009868A (es) Muteinas de interleucina-2 para el tratamiento de enfermedades autoinmunitarias.
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
GEAP202516706A (en) Cyclic peptides for trapping interleukin-1 beta
MX2024014216A (es) Compuestos aromaticos que contienen boro y analogos de insulina relacionados
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MX2026000276A (es) Composiciones y metodos para tratar la esclerosis multiple
MX2022007175A (es) Compuestos y su uso para el tratamiento de la deficiencia de a1-antitripsina.
MX2022000433A (es) Proteinas de fusion a toxina para el tratamiento de enfermedades relacionadas con infecciones por cmv.
MX2024010401A (es) Quiméricos dirigido a proteólisis (protac) de proteína de translocación del linfoma del tejido linfoide asociado a las mucosas 1 (malt1)
ZA202401042B (en) Protein compositions for the treatment of inflammatory diseases
MY203365A (en) Montelukast for the treatment of erosive hand osteoarthritis
GEAP202516774A (en) Compactable oral formulations of ibutamoren
SA520420147B1 (ar) ("tcd") مثبطات إفراز بروتين أساسها تراي أزا سيكلو دوديكان سلفوناميد
MX2023012442A (es) Inhibidores de la ferroportina modificados.
MX2022014197A (es) Usos y formulaciones de cannabinoides.